Identifying Pancreatic Atrophy on Endoscopic Ultrasound

Key EUS Features of Pancreatic Atrophy

On EUS, pancreatic atrophy appears as a hyperechoic pancreatic parenchyma with reduced gland size, often accompanied by prominent lobular segmentation, and may show dilated pancreatic ducts with surrounding hypoechoic areas representing lobulocentric changes, as reported by the American Gastroenterological Association 1, 2
In high-risk individuals undergoing pancreatic surveillance, subtle non-specific parenchymal abnormalities detected by EUS may represent effects of PanIN with associated lobulocentric atrophy, according to the American College of Gastroenterology 1, 2

EUS diagnostic yield is highly operator-dependent, and interpretation of pancreatic atrophy can be affected by interobserver variability, as noted by the European Society of Gastrointestinal Endoscopy 1, 2
When evaluating for atrophy in the context of acute or recurrent pancreatitis, delay EUS for 2-6 weeks after resolution of acute inflammation, as persistent inflammatory changes can hinder accurate assessment of underlying atrophic changes, as recommended by the American Gastroenterological Association 3, 4

In patients over 40 years presenting with unexplained pancreatitis or pancreatic findings, EUS should be performed to exclude occult malignancy that may be causing secondary atrophy, according to the American College of Gastroenterology 5
For individuals with familial pancreatic cancer risk or genetic predisposition, EUS serves as a first-line surveillance test and can identify subtle atrophic changes that may represent early neoplastic processes, as stated by the International Association of Pancreatology 1, 2